HCW Biologics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
HCWB$1.02-1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of operations
Condensed Statements of Operations
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2023 | 2024 | 2023 | 2024 | |
| Revenues: | ||||
| Revenues | $853,102 | $426,423 | $1,517,792 | $2,171,988 |
| Cost of revenues | (678,325) | (341,138) | (1,210,077) | (1,291,546) |
| Net revenues | 174,777 | 85,285 | 307,715 | 880,442 |
| Operating expenses: | ||||
| Research and development | 1,667,442 | 1,186,913 | 5,539,919 | 5,339,383 |
| General and administrative | 1,509,936 | 1,639,152 | 5,106,674 | 4,799,437 |
| Legal expenses | 2,075,279 | 949,455 | 4,610,091 | 15,761,531 |
| Nonoperating loss | — | — | — | 1,300,000 |
| Total operating expenses | 5,252,657 | 3,775,520 | 15,256,684 | 27,200,351 |
| Loss from operations | (5,077,880) | (3,690,235) | (14,948,969) | (26,319,909) |
| Interest expense | (95,514) | (223,363) | (284,465) | (383,029) |
| Other (expense) income, net | 234,753 | 11,310 | 919,688 | 52,397 |
| Net loss | $(4,938,641) | $(3,902,288) | $(14,313,746) | $(26,650,541) |
| Net loss per share, basic and diluted | $(0.14) | $(0.10) | $(0.40) | $(0.71) |
| Weighted average shares outstanding, basic and diluted | 35,926,921 | 37,823,394 | 35,907,123 | 37,623,459 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.